AffiliationDepartment of Medical Oncology, Cancer Research UK, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractOvarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
CitationAntiangiogenic drugs in ovarian cancer. 2009, 100 (1):1-7 Br. J. Cancer
JournalBritish Journal of Cancer
- Angiogenesis as a strategic target for ovarian cancer therapy.
- Authors: Spannuth WA, Sood AK, Coleman RL
- Issue date: 2008 Apr
- Angiogenesis inhibitors for the treatment of ovarian cancer.
- Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
- Issue date: 2011 Sep 7
- Bevacizumab in the treatment of ovarian cancer.
- Authors: Han ES, Monk BJ
- Issue date: 2007 Oct
- Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
- Authors: Liotta M, Rose PG, Escobar PF
- Issue date: 2009 Nov
- Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
- Authors: Teoh D, Secord AA
- Issue date: 2012 Mar